ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Multicentre study of inoperable HPV-negative head and neck cancer: a persistent real-world challenge.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HPV-negative head and neck squamous cell carcinoma (HNSCC) has a poorer prognosis than HPV-positive tumours, yet real-world outcomes remain understudied. This study analyses a multicentre cohort of HPV-negative HNSCC patients, including those over 65 years of age. Materials and methods: This retrospective study included HPV-negative HNSCC patients treated with definitive radiotherapy (RT) or chemoradiotherapy (CRT) between 2015 and 2020. RT protocols included standard fractionation (70 Gy, 35 fractions), simultaneous integrated boost (69.96 Gy, 33 fractions), or concomitant boost (72.5 Gy, 50 fractions). Results: Among 225 patients (62 over 65 years), 138 (61%) received CRT. Local progression occurred in 83 (37%), and 177 (79%) died. Median overall survival (OS) was 23.1 months, with 3-year OS and local control (LC) rates of 37% and 35%, respectively. ECOG predicted outcomes (p < 0.001 for OS, p = 0.040 for LC), while comorbidity burden and disease stage were significant only for OS (p < 0.001 and p = 0.006). CRT improved OS over RT alone (p = 0.059). Older patients more often had hypopharyngeal/laryngeal tumours (p = 0.033), received CRT less frequently (29% Conclusions: Real-world outcomes for inoperable HPV-negative HNSCC remain poor. Personalized approaches are needed to improve care for this challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.